AbbVie (XSWX:ABBV) Other Operating Expense: CHF-192 Mil (TTM As of Mar. 2026)


XSWX:ABBV AbbVie Inc XSWX:ABBV
65 GF Score
Price CHF206.75
GF Value CHF167.66
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Other Operating Expense?

AbbVie XSWX:ABBV 65 Other Operating Expense is CHF-192 Mil as of Mar. 2026. GuruFocus rates XSWX:ABBV with a GF Score™ of 65/100 and a GF Value™ of CHF167.66 (Modestly Overvalued). The stock has 4 warning signs investors should review.

AbbVie's Other Operating Expense for the three months ended in Mar. 2026 was CHF0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-192 Mil.

AbbVie's quarterly Other Operating Expense declined from Sep. 2025 (CHF0 Mil) to Dec. 2025 (CHF-173 Mil) but then increased from Dec. 2025 (CHF-173 Mil) to Mar. 2026 (CHF0 Mil).

AbbVie's annual Other Operating Expense increased from Dec. 2023 (CHF-155 Mil) to Dec. 2024 (CHF-6 Mil) but then declined from Dec. 2024 (CHF-6 Mil) to Dec. 2025 (CHF-192 Mil).

AbbVie Other Operating Expense Historical Data

* Premium members only.

The historical data trend for AbbVie's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Other Operating Expense Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 397.87 52.17 -154.80 -6.24 -192.05

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -19.52 0.00 -172.93 0.00
XSWX:ABBV
65GF Score
AbbVie Inc XSWX:ABBV
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-192 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of CHF-192 Mil mean?
AbbVie (XSWX:ABBV) has a Other Operating Expense of CHF-192 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on AbbVie and its competitors.
Is AbbVie's Other Operating Expense too high?
AbbVie's current Other Operating Expense is CHF-192 Mil. Overall, AbbVie has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Other Operating Expense compare to MRK and JNJ?
AbbVie's Other Operating Expense of CHF-192 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on AbbVie and its competitors. AbbVie's current Other Operating Expense is CHF-192 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (XSWX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF167.66, compared to a current price of CHF206.75 — trading 23.3% above its estimated fair value. The current Other Operating Expense is CHF-192 Mil. AbbVie's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For AbbVie (XSWX:ABBV), the current Other Operating Expense is CHF-192 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (XSWX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of CHF206.75 is trading 23.3% above its estimated GF Value™ of CHF167.66. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for XSWX:ABBV:

  • Other Operating Expense: CHF-192 Mil
  • GF Value™: CHF167.66 vs. price of CHF206.75 (23.3% above fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the XSWX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
65GF Score

Get the complete analysis for XSWX:ABBV

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF206.75
Price
CHF167.66
GF Value